Eleonora Cannas

5PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targetsMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jun 12, 2026
A Phase Ib Trial of Copanlisib in Combination with Venetoclax in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma-SAKK 66/18 Trial.

|May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

|Jun 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

Pageof 1

Frequent Collaborators

5 joint publications

Luciano Cascione

5 joint publications

Francesco Bertoni

3 joint publications

Alberto J Arribas

3 joint publications

Emanuele Zucca